Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

Regeneron develops and commercializes Libtayo globally. About Immuneering Corporation ... once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS ...

The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell ...

Regeneron develops and commercializes Libtayo globally ... inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most pancreatic cancers.

We expect regulatory approvals for linvoseltamab in relapsed/refractory multiple myeloma, odronextamab in late-line follicular lymphoma, and the aforementioned Libtayo indication in adjuvant CSCC.

Regeneron hopes for approval in the indication in the second half of this year. Regeneron also is studying Libtayo as a combo therapy with the company’s fianlimab, going up against Keytruda ...